Investment Thesis
SkinHealth Systems exhibits severe financial distress with declining revenue, negative operating and net cash flows, and unsustainable leverage of 6.58x debt-to-equity. While gross margins of 68.5% demonstrate strong product economics, the company cannot cover interest from operations (negative interest coverage ratio), burns cash operationally, and has negligible equity cushion relative to massive debt burden.
Strengths
- Strong gross margin of 68.5% indicates favorable product pricing and cost structure
- Adequate cash reserves of $204.4M provide near-term operational runway
- Improving EPS trend (-0.05 vs prior year) suggests loss reduction trajectory
Risks
- Extreme leverage of 6.58x debt-to-equity with inability to service debt from operations (interest coverage of -0.6x)
- Negative operating cash flow of -$5.6M indicates unsustainable burn rate despite $204.4M cash
- Declining revenue trend (-10% YoY) combined with operating losses suggests deteriorating business fundamentals
- Negligible stockholders' equity of $55.2M against $363.4M long-term debt creates insolvency risk
Key Metrics to Watch
- Operating cash flow trend and path to positive FCF
- Revenue stabilization and return to growth
- Debt reduction strategy and refinancing risk
- Gross margin sustainability amid revenue decline
Financial Metrics
Revenue
64.9M
Net Income
-6.6M
EPS (Diluted)
$-0.05
Free Cash Flow
-5.8M
Total Assets
473.2M
Cash
204.4M
Profitability Ratios
Gross Margin
68.5%
Operating Margin
-2.8%
Net Margin
-10.2%
ROE
-12.0%
ROA
-1.4%
FCF Margin
-8.9%
Balance Sheet & Liquidity
Current Ratio
1.79x
Quick Ratio
1.48x
Debt/Equity
6.58x
Debt/Assets
88.3%
Interest Coverage
-0.59x
Long-term Debt
363.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T13:07:04.254746 |
Data as of: 2026-03-31 |
Powered by Claude AI